Relationship between bradykinesia and cognitive functions in patients with essential tremor
Objective: To investigate the association between bradykinesia, i.e., movement slowness, as objectively assessed with kinematic analysis, and cognitive functions in ET. Background: Bradykinesia in essential…Diagnostic and treatment burden of dystonia in Turkey: a patient journey map
Objective: To assess the burden of access to diagnosis and botulinum neurotoxin (BoNT) treatment in Turkish patients with dystonia and hemifacial spasm (PwD/HFS). Background: Diagnostic…Parkinson’s Progression Markers Initiative (PPMI) prioritizes enrollment of individuals from diverse and underrepresented populations
Objective: To describe the goals and Year 1 initiatives of PPMI Diversity, Equity, and Inclusion (DEI) taskforce Background: Clinical trials under-enroll people with Parkinson’s disease…COVID-19 associated opsoclonus myoclonus ataxia syndrome
Objective: To present a rare neurological syndrome as a potential parainfectious complication of SARS-CoV-2 infection. Background: Օpsoclonus myoclonus syndrome (OMS) is rare complication of the…atrophy of cranial nerves v and viii is a hallmark of rfc1-related disorder
Objective: To assess the usefulness of cranial nerves V (CNV) and VIII (CNVIII) atrophy as a neuroradiological sign to differentiate RFC1-related disorder from spinocerebellar ataxias…Prevalence of sleep disorders in patients with Parkinson’s disease undergoing screening: a retrospective study.
Objective: To determine the prevalence of sleep disorders in patients with Parkinson's disease undergoing sleep screening. Background: 2009 Norlina et al., determined the prevalence of…Comparison of cognitive , affective and autonomic functions in parkinson’s disease patients with and without freezing of gait and its correlation with PET/CT
Objective: To study and compare the cognitive, affective and autonomic domains in Parkinson’s disease patients with and without freezing of gait and to correlate with…Design of a Phase 2 Study of Suvecaltamide in Moderate to Severe Parkinson’s Disease Tremor
Objective: Describe the design of a phase 2 study (NCT05642442) of a once-daily, extended-release formulation of suvecaltamide to treat moderate to severe Parkinson’s disease tremor…Narrative review of the efficacy of the efficacy of transcranial magnetic stimulation with patients with Parkinson disease.
Objective: To evaluate the efficacy of transcranial magnetic stimulation with patients with Parkinson diseases. Background: Parkinson's disease is one of the most common causes of…Speech difficulties and dopaminergic neurodegeneration in Parkinson’s Disease
Objective: To evaluate the association between speech difficulties and neurodegeneration of the putaminal dopaminergic system in people with early-stage treated with symptomatic therapy and advanced-stage…
- « Previous Page
- 1
- …
- 393
- 394
- 395
- 396
- 397
- …
- 1734
- Next Page »